|
(Evonik) -- Essen, Germany-based
Evonik Industries has increased its production capacity for the pharmaceutical
amino acid glycine by 50 percent due to rising demand. This was achieved by
efficiency gains in the production process. Evonik is a major provider of
glycine and manufactures the amino acid at its Chinese Nanning site in
accordance with the strict requirements of cGMP (current Good Manufacturing
Practice) and the European Pharmacopoeia (CEP; Certificate of Suitability of
Monographs of the European Pharmacopoeia). Evonik is investing in a new plant in
Nanning to expand its portfolio of specialty chemical products by milling and
sieving processes. The new qualities are expected to come on the market at the
end of the year.
By upgrading its technologies particularly in the purification process,
Evonik has further improved product quality. "We're now able to provide glycine
in all crystalline forms and particle size distributions requested by
customers," notes Dr. Jean-Louis Philippe, the responsible marketing manager for
the pharmaceutical amino acids.
Evonik is the creative industrial group from Germany. Evonik is active in
over 100 countries around the world. In fiscal 2010 more than 34,000 employees
generated sales of around EUR 13.3 billion and an operating profit (EBITDA) of
about EUR 2.4 billion.
mrcplast.com
| 
